DCVC Opportunity Fund II GP, LLC
Long book
$13.9M
Q1 2026
Positions
2
Top-10 weight
100%
concentration
Last quarter
+29.6%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsDCVC Opportunity Fund II GP, LLC is a diversified fundamental manager, specialised in healthcare (88% of the long book), running a $13.9M US long book across 2 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: RECURSION PHARMACEUTICALS-A, IONQ INC.
Over the last 9 quarters its long book ran on average 0.2pp per quarter behind the S&P 500, beating the index in 3 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-25.1%
Q2 2024
-12.9%
Q3 2024
+87.3%
Q4 2024
-21.7%
Q1 2025
-4.3%
Q2 2025
+27.4%
Q3 2025
-16.2%
Q4 2025
-25.2%
Q1 2026
+29.6%
Sector allocation
Healthcare 87%
Technology 13%
Long book by quarter
What does DCVC Opportunity own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 2 | $13.9M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 2 | $16.6M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 1 | $19.3M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 2 | $115.3M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 2 | $81.5M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 2 | $113.0M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 3 | $97.4M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 3 | $65.9M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 3 | $71.4M | canonical | SEC ↗ |